REDUCTION OF INCIDENCE, MORTALITY AND LENGTH OF STAY WITH VENTILATOR ASSOCIATED PNEUMONIA (VAP) IN COVID-19 AND NOSOCOMIAL RESPIRATORY INFECTIONS IN INTENSIVE CARE UNIT BY IMPROVING ORAL HYGIENE-A SYSTEMATIC REVIEW AND META ANALYSIS

The objective of this review was to evaluate Reduction of Incidence, Mortality and Length of Stay with Ventilator Associated Pneumonia (VAP) in COVID-19 and Nosocomial Respiratory Infections in Intensive Care Unit in adults 18 years and over. Introduction: Inclusion criteria: Patients with nosocomial and respiratory and covid 19 were included with the use of chlorhexidine or other topical agents or devices used for oral hygiene maintenance in ICU patients compared to a placebo product or usual care were included. Methods: Databases to be searched include PubMed, Google scholar and Cochrane Following the search, titles and abstracts will be screened by two independent reviewers for assessment against the inclusion criteria for the review. The full text of selected citations will be assessed in detail against the inclusion criteria, and studies selected for retrieval will be assessed by two independent reviewers for methodological validity using JBI critical appraisal tools. Studies will not be excluded based on their quality assessment. Results: 41 Studies met the inclusion criteria for review were taken and those studies were statistically pooled studies and outcomes were measured. All the studies demonstrated the by reducing Incidence, mortality and length of stay. Conclusion: VAP Care can help reduce the risk of acquiring lung infection as well as improve ICU efficiency by reducing the staff time needed for manual suctioning. VAPCare is a safe system that did not cause any injury or side effects in the patient population, and also performed as intended Prospero Number: CRD42021233859